|
|
|
|
|
|
|
|
|
|
Verastem
Updated: May 9, 2013, 2:27pm EDT
Verastem Inc. (Nasdaq: VSTM) in Cambridge, Mass. narrowly missed analyst estimates for earnings for the first three months of its fiscal 2013.
The biotech, which is developing drugs aimed at killing cancer stem cells, and has a late-stage trial planned against mesothelioma, and another one underway against ovarian cancer, reported a net loss of $9 million for its first quarter, or 44 cents a share. Analysts were anticipating a loss of 43 cents a share. The company’s stock was down about 1 percent to $9.65 on the news......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.